EP0428608A1 - Arzneimittel- und/oder diät-zubereitungen die l-karnitin und l-lysin enthalten - Google Patents

Arzneimittel- und/oder diät-zubereitungen die l-karnitin und l-lysin enthalten

Info

Publication number
EP0428608A1
EP0428608A1 EP89909580A EP89909580A EP0428608A1 EP 0428608 A1 EP0428608 A1 EP 0428608A1 EP 89909580 A EP89909580 A EP 89909580A EP 89909580 A EP89909580 A EP 89909580A EP 0428608 A1 EP0428608 A1 EP 0428608A1
Authority
EP
European Patent Office
Prior art keywords
carnitine
lysine
compositions according
nsb
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89909580A
Other languages
English (en)
French (fr)
Inventor
Henri Laborit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Roger Bellon SA
Original Assignee
Laboratoire Roger Bellon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Roger Bellon SA filed Critical Laboratoire Roger Bellon SA
Publication of EP0428608A1 publication Critical patent/EP0428608A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • compositions containing L-carnitine and L-Lysine are provided.
  • the present invention generally relates to new pharmaceutical and / or dietetic compositions containing L-carnitine and L-lysine.
  • D, L-carnitine is well known in eating disorders and in muscular disorders of the dystrophic type.
  • the use of D, L-carnitine for the treatment of heart failure is described in US Patents 3,830,931 and 3,968,241.
  • document FR 2 482 588 describes the use of L-carnitine in the treatment of patients suffering from juvenile diabetes mellitus.
  • L-carnitine acts as a co-factor and as a protective agent for cellular energy processes, especially in t i s su s rich in mitochondria, such as muscles and myocardium.
  • L-carnitine More generally, the physiological and pharmacological properties of L-carnitine have been the subject of the following recent publications:
  • L-lysine or its organic acid salts or inorganic, exerts a potentiating or synergistic effect vis-à-vis the biological effects of L-carnitine.
  • the present invention relates more particularly to new pharmaceutical and / or dietetic compositions characterized in that they contain as a single ingredient active L-carnitine, in combination with L-lysine or one of its organic or inorganic acid salts.
  • compositions according to the invention exert favorable effects at the level of the nitrogenous hydrocarbon or electrolytic metabolism of various tissues, and, consequently, at the level of the functions of these in different physiological or pathological situations, in particular when these are accompanied by disturbances of muscle functions (hypoexcitability, hypocontractility).
  • compositions will therefore find application in particular in the treatment of undernutrition states (post-operative, post-infection, post-trauma, post-chemotherapy, chronic respiratory failure, the elderly, the newborn), prediabetes or diabetics, hyperlipemia or in the treatment of heart disease (angina, heart failure), liver failure, cirrhosis.
  • undernutrition states post-operative, post-infection, post-trauma, post-chemotherapy, chronic respiratory failure, the elderly, the newborn
  • prediabetes or diabetics hyperlipemia or in the treatment of heart disease (angina, heart failure), liver failure, cirrhosis.
  • These compositions can also be used in hemodialysis patients.
  • compositions according to the invention can constitute a nutritional supplement in convalescent subjects, the elderly, the occasional or high-level sportsperson, pregnant women and, in general, in any asthenic person who presents functional muscular disturbances ( hypoexcitability and hypocontractility).
  • L-lysine base but also by all the organic or inorganic acid salts of L-lysine which are biologically acceptable.
  • L-lysine following: hydrochloride, acetate, succinate,
  • the combination L-lysine and L-carnitine is a direct combination in the form of a salt.
  • Such salts can be prepared according to traditional methods, for example by mixing L-carnitine with L-lysine in the form of hydrochloride in water and crystallization of the resulting salt by addition of an organic polar solvent immiscible in the water.
  • the relative proportions of L-carnitine and L-lysine can vary between 1: 0.5 and 1:20 in moles.
  • the 24-hour doses of L-carnitine are between 0.5 and 3 g (i.e. 1.13 g to 6.78 g of the equimolar combination of L-carnitine and L -lysine, HCl), i.e. between 1 and 6 g for the equimolar combination.
  • the doses per 24 h of L-lysine are between 0.5 g and
  • the 20 g dose of L-lysine corresponds to the 24-hour supply of certain amino acid solutions used in artificial parenteral nutrition.
  • the invention also relates to the use of L-lysine to potentiate the effect of L-carnitine in the preparation of a medicament intended for the treatment of muscular disturbances linked to hypoexcitability or hypocontractility.
  • the animals are then divided into separate lots and isolated in individual cages. They receive water ad libitum.
  • the products are dissolved in 0.9% isotonic saline.
  • Neuromuscular preparation (sciatic nerve - rocnemian gastric muscle in situ)
  • the method of studying muscle response is based on that described by Charlton M. P. et al. (1981) on the mouse (Intracellular potassium activities in muscles of normal and dystrophic mice: an in vivo electrometric study. Experimental Neurology, 71: 203-219), and repeated by Russell et al. (1983), mentioned above and Russell D. McR. et al. (1984) on the rat (Metabolic and structural changes in skeletal muscle during hypocaloric dieting; Am. J. Clin. Nutr., 39: 503-513).
  • the animal is anesthetized with veterinary sodium pentobarbital at a dose of 30 mg / kg, i.p. (0.05 ml per 100 g body weight).
  • the right femoral vein is catheterized (Abbocath catheter, T 22G x 32 mm) and perfused with a dilute solution (1%) of veterinary sodium pentobarbital.
  • an automatic infuser B. Braun, Melsungen is used at the speed of 0.380 ml / h.
  • the animal is placed on the right flank.
  • the left hind leg is shaved.
  • An incision is made of the skin parallel to the femur and tibia to the base of the calcaneum.
  • the skin is separated from the underlying muscle masses, then an incision of the fascia is made under the same conditions as those used to incise the skin.
  • the muscles are separated while preserving their respective vasculari sation and the common tendon is isolated between the gastrocnemius muscle and the solar muscle.
  • the minimum tension exerted on the muscle is calibrated at 1 g.
  • the sciatic nerve is identified and isolated 2 or 3 cm long and attached by a silk thread about 3 cm from the gastrocnemius.
  • the lateral branches of the sciatic nerve are isolated and severed.
  • a stimulation microelectrode is applied to the sciatic nerve about 1 cm from the gastrocnemius.
  • the animal is placed on a cork board, the left hind leg fixed at the level of the tibia using a trigger guard stabilizing the preparation. It remains at rest for 1 hour in a thermostatically controlled enclosure which maintains the rectal temperature of the animal at 38 C, throughout the handling.
  • the nerve-muscle preparation is bathed in a modified Liley solution suitably oxygenated (95% O 2 and 5% CO 2 ) at 37 ° C, (137 mM / l NaCl; 5 mM / l KCl; 2 mM / l CaCl 2 ; 1 mM / l MgCl 2 ; 24 mM / l NaHCO 3 ; 1 mM / l sodium glutamate and 10 mM / l BES (N, N-b ⁇ s [2-hydroxyethyl] -2-aminoethanesulfonic acid).
  • a modified Liley solution suitably oxygenated (95% O 2 and 5% CO 2 ) at 37 ° C, (137 mM / l NaCl; 5 mM / l KCl; 2 mM / l CaCl 2 ; 1 mM / l MgCl 2 ; 24 mM / l NaHCO
  • Neuro-muscular excitability is determined by measuring 3 parameters: rheobase, chronaxia and useful time according to the methods described by LABORIT H. and LABORIT G., (1955), mentioned above and LAPICQUE L. (1926) "Excitability as a function of time.” 1 vol. Presses Universitaires éd., Paris.
  • Rheobase is the threshold of electrical intensity capable of provoking the minimum functional response of the muscle when the current passage time lengthens indefinitely. This minimum intensity remains the same beyond a certain time limit called useful time. If the current passage time becomes less than the useful time. the intensity of the current capable of provoking a functional response becomes stronger and stronger. For a current of double intensity of the rheobase, the shortest duration of the passage of the exciting current is the chronaxie.
  • Muscle contractility is determined by measuring the force of contraction caused by a stimulation of frequency 10 Hz compared to the force of contraction caused by a stimulation of frequency 100 Hz (maximum force of contraction).
  • the relationship between the force of muscular contraction and the frequency of stimulation is studied by measuring, twice consecutively for a given frequency, the amplitude of the muscular contraction for increasing stimulation frequencies, delivered for 2 s, one per minute of: 10, 20, 30, 40, 50 and 100 Hz.
  • the proportion 1: 0.25 has only a negligible effect while the effect is more marked for the proportion 1: 0.5.
  • the effect remains weak and not significant for doses 2, 4 and 8 times higher, respectively.
  • L-lysine alone does not exercise the activity manifested by the combination L-carnitine + L-lysine.
  • the combination L-carnitine + L-lysine therefore exhibits an increased activity (potentiating or synergistic effect) which can be explained by an increase in biliodispersibility of L-carnitine, at the level of the target organs, muscles and myocardium.
  • the increase in bioavailability of L-carnitine would result first of all from the endogenous synthesis of this one from L-lysine, which thus plays the role of prodrug.
  • the endogenous synthesis mechanism makes it possible to decrease the plasma peaks of L-carnitine, which reduces the risks of urinary loss, while ensuring a better yield of Tissue uptake of L-carnitine by the muscles and by the myocardium thanks to an instantaneous-delay distribution kinetics.
  • n 8 aaa aa aaa aaa aaa
  • n 8 b NSb NSb NSb
  • n 8 bbb b b bbb
  • a comparison with fed controls a or b 0.01 ⁇ P ⁇ 0.1 aa or bb: 0.001 ⁇ P ⁇ 0.02
  • n 8 aaa aa aa aa aaaa
  • n 8 NSb NSb NSb NSb
  • n 8 bbb bbb bbbb
  • n 8 NSb NSb NSb NSb
  • n 8 b ccc NSb c NSb NSc NSb NSc
  • n 8 bb ce NSb NSc NSb NSc NSb c
  • n 8 bbb bb b b
  • n 8 NSa NSa NSa NSa
  • n 7 NSa NSa NSa NSa
  • n 8 NSa NSa NSa NSa a: comparison with the group receiving the mixture 1: 1 NSa: not significant
  • Table IV gives the results of an effect-dose study of an equimolar combination of L-carnitine and L-lysine on the excitability and muscle contractility of the fasted rat (P.O. route).
  • the minimum active dose is close to 20 ⁇ M / kg.
  • the maximum activity is reached at a dose of 77.5 ⁇ M / kg.
  • the doses ( ⁇ M / kg) of the equimolar mixture of L-carnitine and L-lysine are approximately 3 times less than those of L-carnitine alone.
  • the gain in synergy is therefore 3.
  • compositions according to the invention have an obvious interest, not only from the economic point of view, but also with regard to the doses of L-carnitine to be absorbed.
  • n 8 aaa aa aaa aaa aaa
  • n 8 b NSb NSb NSb
  • n 8 bbb b NSb b
  • n 8 bbb bbb b bbbb
  • n 8 bbb bbb bbb bbb
  • Tables V and VI represent the compared effects of L-carnitine associated with L-lysine and respectively of L-carnitine associated in mixture in aqueous solution with L-arginine (Table V), L-ornithine or aspartic acid (Table VI).
  • L-carnitine or DL-carnitine with L-lysine on neuromuscular excitability and on muscle contractility of the fasted rat
  • n 8 aaa aa aa aa aaaa
  • n 8 NSb b NSb NSb
  • n 8 bbb bbb bbbb
  • n 8 bbb NSb NSb bb
  • n 8 aaa aa aa aa aaaa
  • n 8 NSb NSb NSb NSb
  • n 8 bbb bb bb bbb
  • n 8 NSb NSb NSb NSb
  • n 8 bbb NSb NSb NSb
  • n 8 NSb c NSb c NSb NSc NSb c
  • n 8 bbb dddd bb NSd bbb NSd bbb d a: sound comparison with fed controls; a: 0.01 ⁇ P ⁇ 0.1 aa: 0.001 ⁇ P ⁇ 0.02 aaa: P ⁇ 0.001 NSa: not significant.
  • b comparison with fasting witnesses; b, bb, bbb, NSb: see a.
  • c comparison between DL-carnitine + L-lysine and L-carnitine + L-lysine (38.75 ⁇ M / kg); c, cc, ccc, NSc: see a.
  • d identical to c for the dose of 77.50 ⁇ M / kg; d, dd, ddd, NSd: see a.
  • L-carnitine and L-lysine according to the invention can be presented in various forms intended for pharmaceutical or dietetic use.
  • the presentations can be intended:
  • oral solutions ampoules, vials, pack, bags
  • drops syrups, sachets, oral lyophilisates (lyocs)
  • capsules tablets, chewable tablets, reconstituting drinks.
  • parenteral artificial nutrition solutions (carbohydrates, amino acids, peptides, lipids, electrolytes, trace elements, vitamins).
  • Example 2 Drinkable ampoules
  • the invention also relates to a process for the preparation of a pharmaceutical and / or dietetic composition, characterized in that L-carnitine is combined with L-lysine or one of its salts of organic or inorganic acid and in that this combination is mixed with pharmaceutically or dietically acceptable excipients.
  • L-carnitine is combined with L-lysine or one of its salts of organic or inorganic acid and in that this combination is mixed with pharmaceutically or dietically acceptable excipients.
  • the particular embodiments are in accordance with those previously described for the composition.
  • the invention finally relates to a method of treating mammals, in particular a human or an animal, characterized in that a mammal is administered a combination of L-carnitine and L-lysine or one of its organic acid salts or inorganic.
  • physiological or pathological situations are treated, in particular muscular disturbances accompanied by hypoexcitability and / or hypocontractility.
  • muscular like for example the states of malnutrition, the prediabetic or diabetic states, in the hemodyalysis, the hyperlipemias, the cardiopathies and the hepatic insufficiencies.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP89909580A 1988-08-12 1989-08-10 Arzneimittel- und/oder diät-zubereitungen die l-karnitin und l-lysin enthalten Pending EP0428608A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8810886A FR2635264B1 (fr) 1988-08-12 1988-08-12 Compositions pharmaceutiques et/ou dietetiques contenant de la l-carnitine et de la l-lysine
FR8810886 1988-08-12

Publications (1)

Publication Number Publication Date
EP0428608A1 true EP0428608A1 (de) 1991-05-29

Family

ID=9369324

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89909580A Pending EP0428608A1 (de) 1988-08-12 1989-08-10 Arzneimittel- und/oder diät-zubereitungen die l-karnitin und l-lysin enthalten
EP89402257A Expired - Lifetime EP0354848B1 (de) 1988-08-12 1989-08-10 Pharmazeutische und/oder diätetische Zusammensetzungen mit Gehalt an L-Carnitin und L-Lysin

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP89402257A Expired - Lifetime EP0354848B1 (de) 1988-08-12 1989-08-10 Pharmazeutische und/oder diätetische Zusammensetzungen mit Gehalt an L-Carnitin und L-Lysin

Country Status (10)

Country Link
EP (2) EP0428608A1 (de)
JP (1) JP2785989B2 (de)
AT (1) ATE82122T1 (de)
CA (1) CA1341260C (de)
DE (2) DE68903448T2 (de)
ES (1) ES2043062T3 (de)
FR (1) FR2635264B1 (de)
GR (2) GR900300149T1 (de)
PT (1) PT91430B (de)
WO (1) WO1990001316A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660557B1 (fr) * 1990-04-09 1994-05-27 Endobio Groupe Etu Rech Risqu Compositions pharmaceutiques et/ou dietetiques contenant de la carnitine, de la lysine et de la methionine avec ou sans acide pantothenique.
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
IT1306147B1 (it) * 1999-05-28 2001-05-30 Biosalts Srl Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
IT1306186B1 (it) 1999-09-03 2001-05-30 Biosalts Srl Sali non igroscopici di principi attivi ad attivita' terapeutica e/onutrizionale e composizioni atte alla somministrazione orale
IT1317042B1 (it) 2000-06-14 2003-05-26 Biosalts Srl Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
WO2017002718A1 (ja) * 2015-07-01 2017-01-05 株式会社明治 継粉形成抑制剤
US11224582B2 (en) 2017-04-25 2022-01-18 Almeda Labs Llc Amino acid formulations for pancreatic viability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4465M (de) * 1965-06-28 1966-09-26
FR2119882A1 (en) * 1970-12-31 1972-08-11 Prugnaud Robert Calcium hypophosphite-ascorbate/carnitine compsn - used as appetite stimulant
US3968241A (en) * 1972-11-06 1976-07-06 Defelice Stephen L Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9001316A1 *

Also Published As

Publication number Publication date
DE68903448T2 (de) 1993-03-18
JP2785989B2 (ja) 1998-08-13
PT91430B (pt) 1995-05-31
PT91430A (pt) 1990-03-08
JPH04500073A (ja) 1992-01-09
DE68903448D1 (de) 1992-12-17
CA1341260C (fr) 2001-06-19
WO1990001316A1 (fr) 1990-02-22
EP0354848B1 (de) 1992-11-11
ATE82122T1 (de) 1992-11-15
GR3006598T3 (de) 1993-06-30
GR900300149T1 (en) 1991-09-27
FR2635264B1 (fr) 1992-02-28
DE354848T1 (de) 1992-05-21
EP0354848A1 (de) 1990-02-14
ES2043062T3 (es) 1993-12-16
FR2635264A1 (fr) 1990-02-16

Similar Documents

Publication Publication Date Title
JP4850986B2 (ja) カルノシンあるいはその誘導体および分枝アミノ酸を含む抗酸化活性を有する医薬組成物および／または栄養組成物
US7790688B2 (en) Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
DE60308810T2 (de) Anregung der in-vivo synthese von proteinen mit zusammensetzungen enthaltend leucin
AU694125B2 (en) Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
CA2344893C (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
US11219632B2 (en) Skin pigmentation inhibitor
HUE032486T2 (en) An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
PL212737B1 (pl) Kompozycja przeciwutleniajaca zawierajaca acetylo-L-karnityne oraz kwas α-liponowy i jej zastosowanie
EP3668328A1 (de) Zusammensetzungen und verfahren zur erhöhung der muskelmasse und der stärke, behandlung der haut, verminderung der abnutzung und des abbaus durch alterung und belastung und verbesserung der regeneration von stress wie training und trauma
DE60125191T2 (de) Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion
JP2006506361A (ja) カルニチンおよび酸化防止ポリフェノールの治療用組合せ
EP0354848B1 (de) Pharmazeutische und/oder diätetische Zusammensetzungen mit Gehalt an L-Carnitin und L-Lysin
RU2152787C2 (ru) Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
EP0363337A1 (de) Energiesubstrat, das Hydroxycarbonsäure enthält
RU2436415C2 (ru) Композиция биологически активных веществ на основе бетулина с регулируемой скоростью высвобождения компонентов для снижения степени алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома
US20080095865A1 (en) Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance
FR2660557A1 (fr) Compositions pharmaceutiques et/ou dietetiques contenant de la carnitine, de la lysine et de la methionine avec ou sans acide pantothenique.

Legal Events

Date Code Title Description
ITCL It: translation for ep claims filed

Representative=s name: JACOBACCI CASETTA & PERANI S.P.A.

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

TCNL Nl: translation of patent claims filed
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89402257.3/0354848 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 04.09.91.

17Q First examination report despatched

Effective date: 19910904